Who’s Going to Antibody Engineering 2026

Dec 13–16, 2026 San Diego, CA ~900 attendees Website

153 companies and 113 speakers at Antibody Engineering 2026, a ~900-person, mostly biopharma meeting of antibody and protein engineers. As of Sep 26, 2026.

Showing 1–11 of 153 organizations

Organization	Antibody Engineering 2026 Attendance
Xencor Pasadena, CA
xencor.com Biotech Develops engineered antibodies using its XmAb Fc and bispecific technologies, for cancer and autoimmune diseases.	Talk Sun Dec 13 1:00pm–1:15pm Co-Chairs' Remarks: From Discovery to IND: What Matters Most and How to Get it Right Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Amgen Talk Sun Dec 13 4:15pm–5:00pm Moderated Panel Discussion with Session Speakers Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Amgen Talk Mon Dec 14 8:00am–8:05am Co-Chairs' Welcome and Opening Remarks Keynote Presentations - Livestream · with Gyes Talk Mon Dec 14 10:55am–11:30am Jim Huston Science Talent Award and Presentation: Keynote Presentations - Livestream · with Dana-Farber Cancer Institute Talk Wed Dec 16 8:10am–8:15am Co-Chairs’ Remarks Track 2: Engineering Antibody Interfaces: Unlocking New Biology · with Dualitas Therapeutics Talk Wed Dec 16 9:15am–9:45am XenLock™ Fab domains for controlled heavy-light chain pairing in native-like 1+1 bispecific antibodies with extended half-life Redesigned antibody arms that pair only with their intended partner, used to build two-target antibodies that last longer in blood. Bispecifics & multispecifics
AstraZeneca Cambridge, United Kingdom
astrazeneca.com Large pharma Global pharmaceutical company developing antibodies, antibody-drug conjugates and multispecifics in oncology and other diseases.	Talk Sun Dec 13 11:00am–11:45am Career Path/Experiences Panel Discussion Early Career Scientist Session · with Macaw Therapeutics, Genentech Keynote Mon Dec 14 10:20am–10:55am From Insight to Impact: Translational Medicine as a Driver of ADC Clinical Success and Future Innovation Why finding biological markers of response early helps antibodies carrying a cell-killing drug succeed in patients. ADCs & conjugates Talk Wed Dec 16 10:30am–11:00am CD8-Guided T Cell Engager with Potent Preclinical Efficacy and Superior Therapeutic Index An antibody that pulls killer T cells onto liver cancer cells while rousing fewer of the T cells that drive dangerous immune reactions. Talk Wed Dec 16 2:10pm–2:15pm Co-Chairs' Remarks Track 1: Beyond Classic ADCs: Novel Payloads, Modalities & Mechanisms · with Washington University School of Medicine Talk Wed Dec 16 2:15pm–2:45pm Expanding the Toolbox: Non-natural Amino Acids Enable Development of a CD30 Dual-payload ADC Track 1: Beyond Classic ADCs: Novel Payloads, Modalities & Mechanisms
Genentech South San Francisco, CA
gene.com Large pharma Biotechnology company and Roche Group member that discovers, develops and markets antibody and other medicines.	Talk Sun Dec 13 11:00am–11:45am Career Path/Experiences Panel Discussion Early Career Scientist Session · with Macaw Therapeutics, AstraZeneca Talk Mon Dec 14 2:30pm–3:00pm Dissecting the Mechanisms of Action of PROTABs: Insights into Designing Antibody-Based Protein Degraders How the shape of antibody binding decides whether a target protein on the cell surface is actually destroyed. Bispecifics & multispecifics Talk Tue Dec 15 8:10am–8:15am Co-Chairs’ Remarks Track 1: Advanced In Vivo Approaches to Antibody Discovery · with Johnson & Johnson Talk Tue Dec 15 8:15am–8:45am From COVID to Cancer: LNP-mRNA as an Antigen Format for Antibody Discovery Against Challenging Membrane Proteins Immunizing animals with mRNA packaged in tiny fat particles, so their antibodies recognize proteins embedded in cell membranes. Protein engineering
Regeneron Tarrytown, NY
regeneron.com Large pharma Biotechnology company that discovers, develops and markets antibody medicines, including bispecific antibodies, using its VelocImmune mouse platform.	Talk Sun Dec 13 3:45pm–4:15pm From Molecule Design to Approved Regimens: A Clinical Pharmacology Perspective on Dose Selection for Next-Generation Biologics How measurements of drug levels and effects in the body guide the first human dose and the final approved dosing schedule. Talk Mon Dec 14 5:15pm–5:45pm Targeting IgE Responses Track 2: Engineering Solutions for Accessing Difficult Targets Beyond oncology Talk Wed Dec 16 8:10am–8:15am Co-Chairs’ Remarks Track 1: Beyond Bispecifics: Next Wave of Tri- & Multi-Specific Abs · with Rondo Therapeutics
University of Southampton Southampton, United Kingdom
southampton.ac.uk Academic Public research university whose Centre for Cancer Immunology works on antibody immunotherapy and Fc receptor biology.	Talk Mon Dec 14 2:25pm–2:30pm Co-Chairs’ Remarks Track 2: Engineering Solutions for Accessing Difficult Targets · with Macaw Therapeutics Talk Mon Dec 14 4:45pm–5:15pm Disulfide Engineering of Immunostimulatory Antibodies for Augmented Receptor Agonism and Immune Cell Stimulation Adding chemical bridges between an antibody's two arms to lock its shape and make it switch on immune cells more strongly. Protein engineering Talk Tue Dec 15 8:10am–8:15am Co-Chairs' Remarks Track 2: Antibody Engineering for Proximity-Based Approaches · with Chai Discovery
Amgen Thousand Oaks, CA
amgen.com Large pharma Global biopharmaceutical company developing and manufacturing biologic medicines, including bispecific T-cell engagers.	Talk Sun Dec 13 1:00pm–1:15pm Co-Chairs' Remarks: From Discovery to IND: What Matters Most and How to Get it Right Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Xencor Talk Sun Dec 13 1:15pm–1:45pm Developability-Guided Generative Biology for Therapeutic Protein Engineering Designing new therapeutic proteins by computer while checking from the start that they can be made and purified. AI & computational design Talk Sun Dec 13 4:15pm–5:00pm Moderated Panel Discussion with Session Speakers Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Xencor
RT Rondo Therapeutics Hayward, CA
Biotech Develops bispecific T cell engagers, including co-stimulatory CD28 bispecifics, for solid tumors.	Talk Tue Dec 15 2:25pm–2:30pm Co-Chairs’ Remarks Track 1: Engineering and Biological Principles for Cell Engagers · with National Cancer Institute Talk Tue Dec 15 2:30pm–3:00pm Combination of Signal 1 and Signal 2 T Cell Engagers for Treatment of Ovarian Cancer Pairing two antibodies that give T cells both of the signals they need, aiming at ovarian cancer that no longer responds to platinum drugs. Talk Wed Dec 16 8:10am–8:15am Co-Chairs’ Remarks Track 1: Beyond Bispecifics: Next Wave of Tri- & Multi-Specific Abs · with Regeneron
Alloy Therapeutics Waltham, MA
alloytx.com Discovery platformsGold sponsor Provides ATX transgenic mice, display libraries and discovery services for antibodies and other drug modalities to drug developers.	Booth Exhibiting at Booth 220 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Mon Dec 14 1:45pm–2:15pm Alloy Therapeutics Scientific Briefing Scientific Briefing 4 Antibody discovery Talk Wed Dec 16 7:30am–8:00am VHH and VLL Discovery Using ATX Transgenic Animals and Yeast Displayed Libraries Finding tiny single-piece human antibodies, using engineered mice and yeast-grown libraries, that can reach hidden pockets on a target. Antibody discovery
argenx
argenx.com Biotech Immunology company developing antibody-based medicines for autoimmune diseases, with marketed FcRn-blocking therapy.	Talk Sun Dec 13 9:00am–9:10am Session Co-Chair Welcome and Opening Remarks Short research talks by scientists within ten years of their graduate degree, plus career advice and time to meet peers. with Chai Discovery Talk Wed Dec 16 4:15pm–4:45pm A Novel Antibody Approach to Pan-subclass IgG Reduction An antibody that sweeps up and destroys every subtype of the main antibody class in blood, for diseases caused by self-attacking antibodies. Beyond oncology
Chugai Pharmaceutical Tokyo, Japan
chugai-pharm.co.jp Large pharma Japanese pharmaceutical company and Roche Group member known for antibody engineering technologies such as recycling and bispecific antibodies.	Talk Mon Dec 14 3:30pm–4:00pm Protease-Activated IL-12 Masking via Engineered VH Dissociation and IL-12 Intrinsic activity Enables Tunable Cytokine Activation Caging a powerful immune-signaling protein so it only switches on where tumor enzymes cut the cage open. Talk Tue Dec 15 4:45pm–5:15pm Long Acting Anti-latent TGF-β1 Recycling Antibody for Fibrotic Diseases An antibody that is recycled back out of cells, letting it block a scarring-driving growth factor for far longer. Protein engineering
City of Hope Duarte, CA
cityofhope.org Academic Cancer research and treatment center with a graduate school.	Talk Wed Dec 16 3:15pm–3:45pm MPACT: Engineering the Fc–FcγR Interface for Plug-and-Play, Mixed-Valency Multispecific Antibodies Using a chemical bond at a natural antibody contact point to snap extra targeting or immune-activating parts onto one antibody. Bispecifics & multispecifics Talk Wed Dec 16 4:15pm–4:45pm Turning up the Heat: Radioimmunoconjugates for Targeted Radiation Therapy Using antibodies and smaller antibody pieces to carry radioactive atoms that both image and irradiate tumors.

Instantly find 20 buyers from companies at Antibody Engineering 2026

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

What conference is this?

Antibody Engineering & Therapeutics is Informa Connect’s annual meeting on antibody discovery and engineering, run with The Antibody Society and held December 13–16, 2026 at the Marriott Marquis San Diego Marina. It brings together antibody discovery, protein engineering and developability scientists from pharma, biotech and academia with the discovery-platform, reagent and instrument companies that serve them, across tracks on in vitro and in vivo discovery, bispecifics and multispecifics, cell engagers, antibody–drug conjugates, antibody interfaces and domains, difficult targets, and uses beyond oncology.

What is in this guide?

Every organization we can place at Antibody Engineering 2026: 113 speakers from the public program (127 sessions) rolled up to their companies and institutions, plus the 75 sponsors and exhibitors from the public directory with their booth numbers where published — 153 organizations in one list. Speakers appear as job titles, never by name.

How are organizations typed?

By the role an organization plays in antibody discovery and development: drug developers (large pharma and biotech), then the companies around them — CROs and CDMOs, discovery platforms, reagents, instruments and analytics, software and AI, consulting and other services — and academic, government and non-profit bodies. The topic filters come from the track a session sits in and from each session’s own title and abstract.

How current is it?

Pulled from the public agenda, speaker list and sponsor directory on September 26, 2026. Exhibit-hall hours are the first and last exhibit-hall activity on the public agenda.

Browse Antibody Engineering 2026 by

Organization type

Topic

Exhibit hall

Exhibitors 75

Everyone

All organizations A–Z 153

Organizations with their own page

94 organizations — every exhibitor and every organization with 2 or more presentations.

Not affiliated with or endorsed by Informa Connect, The Antibody Society or Antibody Engineering & Therapeutics. Submit a correction